VR Logo

Revance Therapeutics Inc. (RVNC) download report


Healthcare | Biotechnology & Pharma Research

Revance Therapeutics Inc. (RVNC) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally.

IPO Date: 06-Feb-2014

CEO & Director: Mr. Mark J. Foley

Pres: Mr. Dustin S. Sjuts

Listing: NASDAQ: RVNC

Country: United States

Headquarters: Nashville, TN

Website: https://www.revance.com

Key Facts

Market cap: $1,042.77 Mln

Revenue (TTM): $89.76 Mln

Earnings (TTM): $-274.01 Mln

Cash: $262.59 Mln

Total Debt: $492.47 Mln

Insider's Holding: 2.66%

Liquidity: Low

52 Week range: $11.27 - 33.83

Shares outstanding: 72,768,200

10 Years Aggregate:

  • CFO: $-963.03 Mln
  • EBITDA: $-1,203.26 Mln
  • Net Profit: $-1,322.35 Mln

Stock Performance

Time Period Revance Therapeutics (RVNC) S&P BSE Sensex* S&P Small-Cap 600*
YTD-12.19-8.62-18.78
1 month2.36-4.54-8.00
3 months-26.51-10.19-13.65
1 Year-51.651.43-17.19
3 Years3.3810.146.10
5 Years-11.5011.265.87
10 Years--11.829.84
As on 01-Jul-2022 *As on 04-Jul-2022
Year Revance Therapeutics (RVNC) S&P Small-Cap 600 S&P BSE Sensex
2021-42.4125.2721.99
202074.619.5715.75
2019-19.3720.8614.38
2018-43.52-9.705.87
201772.7111.7327.91
2016-39.4024.741.95
2015101.65-3.36-5.03